Pilar Coronel Granado-rekin lankidetzan egindako argitalpenak (29)

2024

  1. Exploring therapeutic options for mild diabetic-related foot infections: a comparative in vitro study of cefditoren versus amoxicillin/clavulanic acid

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 4, pp. 356-359

2012

  1. Comparative in vitro activity of common antibiotics and relationship with changes in Streptococcus pneumoniae serotypes causing otitis in children prior to and 10 years after introduction of conjugate vaccines in Spain

    International Journal of Antimicrobial Agents

  2. Variations in serotypes and susceptibility of adult non-invasive Streptococcus pneumoniae isolates between the periods before (May 2000-May 2001) and 10 years after (May 2010-May 2011) introduction of conjugate vaccines for child immunisation in Spain

    International Journal of Antimicrobial Agents, Vol. 40, Núm. 1, pp. 18-23

2011

  1. Efficacy of simulated cefditoren versus amoxicillin-clavulanate free concentrations in countering intrastrain ftsI gene diffusion in Haemophilus influenzae

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 6, pp. 2788-2794

2010

  1. Cefditoren versus ceftazidime in inducersubstrate combinations for the evaluation of AmpC production in a disc approximation test

    Revista Espanola de Quimioterapia, Vol. 23, Núm. 2, pp. 72-75

  2. Enhanced in vivo activity of cefditoren in preimmunized mice against penicillin-resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a sepsis model

    PLoS ONE, Vol. 5, Núm. 8

  3. In vitro interference of β-lactams with biofilm development by prevalent community respiratory tract isolates

    International Journal of Antimicrobial Agents, Vol. 35, Núm. 3, pp. 274-277

  4. Susceptibility of recently collected spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccine

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 6, pp. 2696-2698

2009

  1. Genotypic versus phenotypic characterization, with respect to β-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to β-lactam resistance markers

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 1, pp. 267-270

  2. Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different β-lactams: An in vitro pharmacodynamic approach

    Journal of Antimicrobial Chemotherapy, Vol. 63, Núm. 6, pp. 1215-1222

  3. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections

    Revista Espanola de Quimioterapia, Vol. 22, Núm. 2, pp. 57-61

2008

  1. Decrease in bacterial load versus resistance selection of pneumococcal subpopulations by β-lactam physiological concentrations over time: An in vitro pharmacodynamic simulation

    Microbial Drug Resistance, Vol. 14, Núm. 1, pp. 13-21

  2. Efficacy of cefditoren in the treatment of upper respiratory tract infections: A pooled analysis of six clinical trials

    Revista Espanola de Quimioterapia, Vol. 21, Núm. 1, pp. 14-21

  3. High protein binding and cidal activity against penicillin-resistant S. pneumoniae: A cefditoren in vitro pharmacodynamic simulation

    PLoS ONE, Vol. 3, Núm. 7

  4. In vitro activity of oral cephalosporins against pediatric isolates of Streptococcus pneumoniae non-susceptible to penicillin, amoxicillin or erythromycin

    Journal of Chemotherapy, Vol. 20, Núm. 2, pp. 175-179

  5. Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers

    International Journal of Antimicrobial Agents

  6. Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil

    Antimicrobial Agents and Chemotherapy, Vol. 52, Núm. 3, pp. 1184-1186

  7. β-Lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics

    PLoS ONE, Vol. 3, Núm. 12

  8. β-lactam activity against penicillin-resistant Streptococcus pneumoniae strains exhibiting higher amoxicillin versus penicillin minimum inhibitory concentration values: An in vitro pharmacodynamic simulation

    Chemotherapy, Vol. 54, Núm. 2, pp. 84-90

  9. β-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes

    Revista Espanola de Quimioterapia, Vol. 21, Núm. 3, pp. 149-152